| Attributes | Values |
|---|
| rdf:type
| |
| description
| - videnskabelig artikel (da)
- article científic (ca)
- articolo scientifico (it)
- artigo científico (pt)
- bilimsel makale (tr)
- vedecký článok (sk)
- vetenskaplig artikel (sv)
- vědecký článek (cs)
- wetenschappelijk artikel (nl)
- wissenschaftlicher Artikel (de)
- научни чланак (sr)
- article scientifique (fr)
- artículu científicu espublizáu en 2008 (ast)
- наукова стаття, опублікована в серпні 2008 (uk)
- scientific article published on 11 August 2008 (en)
- مقالة علمية نشرت في 11 أغسطس 2008 (ar)
- 2008 թվականի օգոստոսի 11-ին հրատարակված գիտական հոդված (hy)
|
| publication date
| |
| publication date
| |
| author name string
| |
| author name string
| - John Bartlett
- Paul E Goss
- Enrico di Salle
- William R Miller
- Angela M H Brodie
- Thierry Maudelonde
- Nicolai Maass
- Robert W Brueggemeier
- Antonio Llombart
|
| rdfs:label
| - Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? (en)
- Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? (nl)
- Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? (ast)
|
| skos:prefLabel
| - Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? (en)
- Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? (nl)
- Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? (ast)
|
| name
| - Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? (en)
- Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? (nl)
- Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? (ast)
|
| author
| |
| author
| |
| title
| |
| title
| - Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? (en)
|
| page(s)
| |
| page(s)
| |
| instance of
| |
| instance of
| |
| PubMed ID
| |
| PubMed ID
| |
| PubMed ID
| |
| published in
| |
| published in
| |
| issue
| |
| volume
| |
| issue
| |
| volume
| |
| DOI
| |
| DOI
| |
| DOI
| - 10.1634/THEONCOLOGIST.2008-0055
|
| ResearchGate publication ID
| |
| ResearchGate publication ID
| |
| is about
of | |
| is cites work
of | - Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.
- Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.
- Understanding the mechanisms of aromatase inhibitor resistance
- Development of a new class of aromatase inhibitors: design, synthesis and inhibitory activity of 3-phenylchroman-4-one (isoflavanone) derivatives
- Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and -resistant breast cancer cells
- Guidelines for Osteoprotection in Breast Cancer Patients on an Aromatase Inhibitor
- Aromatase inhibitors: prediction of response and nature of resistance
- Aromatase, aromatase inhibitors, and breast cancer
- Status of adjuvant endocrine therapy for breast cancer
- The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies
- Targeting the estrogen pathway for the treatment and prevention of lung cancer
- Molecular docking and 3D-QSAR-based virtual screening of flavonoids as potential aromatase inhibitors against estrogen-dependent breast cancer
- Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement
- Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer
- Management of patients with metastatic breast cancer
- Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer
- Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy
- Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy
- Are we ready to change clinical practice after the 'soft and text' results?
- Apoptosis and autophagy in breast cancer cells following exemestane treatment
- Sulfonanilide Derivatives in Identifying Novel Aromatase Inhibitors by Applying Docking, Virtual Screening, and MD Simulations Studies.
- Strategies and Progress of Endocrine Therapy for Patients with Metastatic Breast Cancer.
- Optimal management of hormone receptor positive metastatic breast cancer in 2016
- Novel inhibitor discovery against aromatase through virtual screening and molecular dynamic simulation: a computational approach in drug design
- Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy
- The Role of Androgen Receptor in Breast Cancer.
|
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)